title: Cost-efficacy comparison of inhaled fluticasone propionate and budesonide in the treatment of asthma.
abstract: BACKGROUND
  The results of a recent meta-analysis comparing 2 inhaled corticosteroids, fluticasone propionate (FP) and budesonide, demonstrated that FP had an improved efficacy-to-safety ratio compared with budesonide. However, limited data are available on the relative economic benefits of these 2 regimens.
  
  
  OBJECTIVE
  This pharmacoeconomic analysis used individual patient data from studies in the meta-analysis to compare the relative cost-efficacy of 2 asthma regimens from the perspective of a US third-party payer.
  
  
  METHODS
  This analysis included all 7 studies in the meta-analysis that compared budesonide with FP dosed at approximately half the dose of budesonide and that included measurement of daily morning peak expiratory flow (PEF).
  
  
  RESULTS
  The total daily per-person cost of asthma management was higher for patients treated with budesonide than with FP ($3.00 vs $2.25, respectively). Treatment with FP had greater cost-efficacy than treatment with budesonide, based on a range of outcome measures that included improvement in morning PEF, symptom-free days, and episode-free days. The daily cost per effectively treated patient (an increase in PEF of > or = 10%) was $5.62 with FP and $10.05 with budesonide. The cost per symptom-free day was $4.36 with FP, compared with $6.67 with budesonide. The cost per episode-free day was $5.60 with FP and $9.42 with budesonide. The pharmacoeconomic difference continued to favor FP as the criteria for success were made more stringent and the cost of budesonide was lowered.
  
  
  CONCLUSIONS
  Based on data from the 7 randomized, controlled trials, treatment of asthma with FP was more effective and less expensive, using US health care assumptions and costs, than treatment with budesonide.
authors.affiliation: Virginia Mason Medical Center, Seattle, Washington 98101, USA. immdas@vmmc.org
authors.forename: D A
authors.initials: DA
authors.lastname: Stempel
authors.forename: R H
authors.initials: RH
authors.lastname: Stanford
authors.forename: R
authors.initials: R
authors.lastname: Thwaites
authors.forename: M J
authors.initials: MJ
authors.lastname: Price
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D000730:Androstadienes / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D019819:Budesonide / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D002648:Child; D003362:Cost-Benefit Analysis; D000068298:Fluticasone; D006801:Humans
chemical_list: D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D019819:Budesonide; D000068298:Fluticasone